Virtual Biotech: Single-Cell-Supported Drug Targets Are 48% More Likely to Reach Market
james_y_zou · x · 2026-09-18
Follow-up on the Virtual Biotech study: agents annotated 57,000 clinical trials, curating scattered outcomes into an open standardized database. Analysis shows drug targets backed by single-cell evidence are 48% more likely to reach market, helping the industry prioritize targets.
More from Research
- Asynchronous Flow Map Language Models Generate All Tokens in a Single Forward Pass — kalyan_kpl · 2026-11-02
- NVIDIA's Kumo Is a Family of Four Tabular Foundation Models, Not Just One — pandeyparul · 2026-11-02
- Economist Aaroth: fast agreement dynamics survive without Bayesian updates or accurate priors — Aaroth · 2026-11-02
- ELLIS names 160 new ML Fellows and Scholars for 2025–2026 — JJitsev · 2026-11-02
- Meme turn 50: Aumann's 'Agreeing to Disagree' paper anniversary — Aaroth · 2026-11-02
- Anthropic: analysts unknowingly adopted their agent's secret lean 86% of the time — shoumikgoswami · 2026-11-02